Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.

PURPOSE Interleukin-6 (IL-6), a proinflammatory cytokine the serum andtissue levels of which are elevated in prostate cancer patients, activates the androgen receptor (AR) in a ligand-independent and synergistic manner. Oncostatin M (OSM) is an IL-6 type cytokine that regulates the growth of prostate cancer cells in a paracrine fashion. The present study was designed to investigate the regulation of AR expression and function by OSM, as well as the efficacy of the nonsteroidal antiandrogens hydroxyflutamide and bicalutamide in the inhibition of AR-mediated signal transduction. EXPERIMENTAL DESIGN Expression of the OSM receptor-beta in the prostate cancer cell lines LNCaP, PC-3, and DU-145 was investigated by reverse transcription-PCR. DU-145 and PC-3 cells were cotransfected with an androgen-responsive gene and AR cDNA. Reporter gene activity was measured after treatment with androgen and/or OSM in the absence or presence of antiandrogens or protein kinase inhibitors. AR expression after OSM treatment was assessed by Western blot. RESULTS OSM receptor-beta expression was higher in DU-145 and PC-3 than in LNCaP cells. OSM caused ligand-independent activation of the AR in DU-145 cells, and the maximal activation was 62% of that induced by the synthetic androgen methyltrienolone. In the presence of OSM, hydroxyflutamide behaved as an AR agonist. Bicalutamide down-regulated AR activation caused by OSM only at a concentration of 1 microM. The inhibitor of the protein kinase A signaling pathway PKI and dn signal transducers and activators of transcription (STAT) 3 showed no effect on AR activation by OSM. The inhibitor of the MAPK pathway, PD 98059, caused only a minor down-regulation of OSM-induced reporter gene activity. OSM did not change AR expression in DU-145 cells transfected with AR cDNA. CONCLUSIONS OSM is a member of the IL-6 family of cytokines, which causes ligand-independent activation of the AR without altering receptor expression. In contrast to AR activation by IL-6, nonsteroidal AR antagonists act as agonists in the presence of OSM. This may be attributable to recruitment of different intermediary signal transduction proteins by OSM and IL-6, respectively. The acquisition of agonistic properties of AR blockers in the presence of OSM might compromise use of these drugs in prostate cancer treatment.

[1]  Jingwen Liu,et al.  Oncostatin M–induced growth inhibition and morphological changes of MDA‐MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway , 2001, Breast Cancer Research and Treatment.

[2]  M. Ittmann,et al.  Interleukin-6 is an autocrine growth factor in human prostate cancer. , 2001, The American journal of pathology.

[3]  H. Klocker,et al.  Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  E. Keller,et al.  Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice , 2001, The Prostate.

[5]  E. Keller,et al.  Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  H. Fuse,et al.  Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. , 2001, Biochemical and biophysical research communications.

[7]  O. Cussenot,et al.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. , 2001, Cancer research.

[8]  E. Keller,et al.  Long‐term exposure of tumor necrosis factor α causes hypersensitivity to androgen and anti‐androgen withdrawal phenomenon in LNCaP prostate cancer cells , 2001 .

[9]  P. Heinrich,et al.  Non-redundant Signal Transduction of Interleukin-6-type Cytokines , 2000, The Journal of Biological Chemistry.

[10]  M. Friedrich,et al.  Oncostatin M‐Mediated Growth Inhibition of Human Glioblastoma Cells Does Not Depend on Stat3 or on Mitogen‐Activated Protein Kinase Activation , 2000, Journal of neurochemistry.

[11]  H. Klocker,et al.  Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue , 2000, The Journal of pathology.

[12]  H. Klocker,et al.  Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides , 2000, Cancer Gene Therapy.

[13]  W. Farrar,et al.  Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.

[14]  T. Chung,et al.  STAT3 mediates IL‐6‐induced growth inhibition in the human prostate cancer cell line LNCaP , 2000, The Prostate.

[15]  T. Chung,et al.  Interleukin‐6 activates phosphatidylinositol‐3 kinase, which inhibits apoptosis in human prostate cancer cell lines , 2000 .

[16]  J. M. Lin,et al.  Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. , 2000, The Prostate.

[17]  Martin R. Schneider,et al.  Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.

[18]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[19]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  B. Bonavida,et al.  Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. , 1999, Biochemical and biophysical research communications.

[21]  M. Sadar.  Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways* , 1999, The Journal of Biological Chemistry.

[22]  B. Bonavida,et al.  Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. , 1999, Anticancer research.

[23]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[24]  J. Simons,et al.  Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.

[25]  G. Ciliberto,et al.  Blocking signaling through the gp130 receptor chain by interleukin‐6 and oncostatin M inhibits PC‐3 cell growth and sensitizes the tumor cells to etoposide and cisplatin‐mediated cytotoxicity , 1999, Cancer.

[26]  M. Kattan,et al.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. , 1999, The Journal of urology.

[27]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[28]  C Darne,et al.  Phorbol ester causes ligand-independent activation of the androgen receptor. , 1998, European journal of biochemistry.

[29]  C. Begley,et al.  Oncostatin M induces the differentiation of breast cancer cells , 1998, International journal of cancer.

[30]  W. Rosner,et al.  Estradiol Activates the Prostate Androgen Receptor and Prostate-specific Antigen Secretion through the Intermediacy of Sex Hormone-binding Globulin* , 1997, The Journal of Biological Chemistry.

[31]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[32]  H. Klocker,et al.  Mutant androgen receptors in prostatic tumors distinguish between amino‐acid‐sequence requirements for transactivation and ligand binding , 1995, International journal of cancer.

[33]  H. Klocker,et al.  Distant metastases from prostatic carcinoma express androgen receptor protein. , 1995, Cancer research.

[34]  J. Simons,et al.  Interleukin-6: a candidate mediator of human prostate cancer morbidity. , 1995, Urology.

[35]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. , 1994, Cancer research.

[36]  H. Scher,et al.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.